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Pharmacotherapy for the prevention of the progression 
of chronic heart failure in elderly patients with coronary 
heart disease
Olga A. Osipova1, Nina I. Zhernakova2, Andrey I. Golovin3, Alfiya E. Pushkareva1, Olga M. Godlevskaya4
INTRODUCTION
An age-related increase in the incidence of chronic heart 
failure (CHF) is due to a number of significant factors: The 
undoubted increase of coronary heart disease (CHD) in 
the modern world, arterial hypertension (AH) - especially 
with their frequent combination; certain successes in 
the treatment of acute and chronic forms of coronary 
artery disease and hypertension, which contributed to 
the chronization of these diseases, an increase in the life 
expectancy of such patients with the development of 
circulatory decompensation; sclerosis and myocardial 
atrophy, increasing atherosclerosis processes. CHF 
occurs as a result of common cardiovascular diseases in 
the elderly, combined with age-related changes in both 
structural and functional characteristics of the heart.[1] 
CHF significantly represents today a geriatric syndrome 
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in much the same way as dementia.[2] Since aging is a 
progressive biological process, it is believed that old age 
begins when an active social contribution is no longer 
possible. Advances in the treatment of cardiovascular 
diseases, in particular, AH, ischemic heart disease (IHD) 
(especially myocardial infarction) and CHF contribute 
to the increasing number of older population.[3] The 
prevalence of clinically pronounced CHF in different 
regions of the Russian Federation is 4.1%.[2] However, 
it is established that in elderly people (60–74 years) 
the incidence of CHF increased up to 7%.[4,5] It should 
be noted that the results of survival on the background 
of drug therapy, for elderly people with heart failure, 
have recently improved, but mortality, hospitalization, 
and re-hospitalization remain still high.[6] The 5-year 
survival of patients with CHF is still >50%, and the risk 
of sudden death is 5 times higher than in the population 
in general.[5]
The mechanisms of CHF progression on the 
background of IHD due to active structural and 
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morphological effects are manifested directly by 
cardiac remodeling due to both cardiomyocytes 
and myocardial fibrosis.[7] However, these general 
provisions need to clarify the features in elderly 
patients against the background of coronary artery 
disease, in particular, in those with acute myocardial 
infarction (AMI). To understand personalized 
mechanisms of cardiac insufficiency development 
in this category an additional use of quantitative 
morphological methods is required since changes in 
tissue and intracellular components in the myocardium 
with increasing or decreasing the functional load on 
the heart are primarily quantitative in nature.[8] At 
present, to determine the tactics of elderly patients 
with CHF after a heart attack, as well as to prevent 
its complications, it is necessary to take into account 
the pathogenetic mechanisms of this process.[2] 
There is ample evidence that CHF develops as two 
different syndromes: Systolic and diastolic heart 
failure. To date, according to the degree of reduction 
of the contractile function of the myocardium of the 
left ventricular (LV), CHF is classified into heart 
failure with low ejection fraction (LEF) (<40%), 
CHF with intermediate EF (IEF) (from 40% to 49%) 
(iCHFEF), and CHF with preserved EF (pEF) (50% 
and more) (pCHFEF), while in healthy individuals 
at physiological rest the normal value of EF is 
considered to be 50–75%, with increase up to 80–
85% during physical exercises in healthy people. 
LCHFEF accounts for 50–70% of cases, iCHFEF 
and pCHFEF - 30–50% of all patients with CHF.[9] 
At present, to determine the management of elderly 
patients with CHF after suffering AMI, as well as to 
prevent its complications, one shall take into account 
the pathogenetic mechanisms of the formation of 
fibrosis, the remodeling of MKM in the 1st year based 
on the age characteristics of this process.[10,11]
Objective
The objective of the study was to study the optimization 
of methods of pharmacotherapy and prevention of the 
progression of CHF in patients with CHD, subject to 
the individual characteristics of the elderly.
MATERIALS AND METHODS
The research was carried out on the basis of the 
Scientific-Educational and Innovation Center 
“Nanostructured Materials and Nanotechnologies,” 
Belgorod State National Research University, 
the resource center “Development of Molecular 
and Cellular Technologies,” St. Petersburg State 
University, Department of Pathological Anatomy 
of City Clinical Hospital №21, Bashkir State 
Medical University, Pathoanatomical Department of 
Prof. A. I. Meshchaninov Municipal Clinical Hospital 
of Emergency Medicine, and Kharkiv Medical 
Academy of Postgraduate Education.
The object of our study was 140 elderly men with CHF 
on the background of long-term chronic coronary artery 
disease who had suffered AMI, whose average age 
was 68.4 ± 7.8 years. All patients had their functional 
class (FC) of CHF determined. It was established 
that FC I was detected in 32 patients (22.8%), FC II 
was established in 50 (35.7%), FC III was detected 
in 46 (32.8%), and FC IV was detected in 12 patients 
(8.7%). The control group consisted of 20 persons 
without cardiovascular diseases comparable in age 
(average age - 66.9 ± 6.4 years). All patients received 
optimal medication; an angiotensin-converting 
enzyme inhibitor, a beta adreno blocker, a competitive 
antagonist of aldosterone, and calcium antagonists; if 
necessary, ivabradine, nitrates/sydnonimines, statins, 
antiaggregant, diuretics, and cardiac glycosides were 
additionally prescribed. Echocardiographic study 
of the heart was performed on Philips En Visor C 
echocardiograph (USA, 2005) with an electronic sensor 
3.5 MHz Vivid-7 (USA, 2004) with a multifrequency 
sensor.[12] The M-model study was performed under 
a two-dimensional viewing of the heart in the 
parasternal position along the long axis of the left 
ventricle LV, involving measurement of thickness 
of the interventricular septum and the posterior wall 
of the left ventricle in systole and diastole (cm), the 
end-diastolic volume, and end-systolic volume of 
the LV (cm), and LV EF (%). To assess the diastolic 
function of the left ventricle, all patients had their 
transmittal blood flow studied by pulsed Doppler 
echocardiography using the standard method on Sim-
5000 Plus apparatus (Biomedica, Italy). The following 
parameters were determined: E - the maximum flow 
velocity of the late reservoir period (cm × s−1), A - the 
maximum flow rate of the late reservoir period 
(cm × s−1), and E/A - the ratio between the amplitudes 
of the E and A waves.
To study the morphological structure of the 
myocardium, autopsies of 27 samples were taken. 
The resulting material was divided into three groups: 
The first group (U1) consisted of patients with LCHFEF 
(included in the “heart transplantation” protocol and 
died of terminal heart failure), whose mean EF was 
27.87±7.6 (27.9 [18.04–35.13]) (n = 10). The second 
group (U2) included patients with pCHFEF (died 
from a hemorrhagic stroke on the background of AH) 
whose mean EF was 61.54 ± 6.3 (61.55 [50.04–67.24]) 
(n = 10). Group U3 (control group) is represented by 
autopsy of the myocardial tissue of healthy individuals 
without cardiovascular disease, who died in road traffic 
accidents (n = 7). To assess the autopsy of dead patients, 
after cardiovascular mass determination (in grams), 
LV heart muscle samples were taken no later than 
12 h from the moment of death. Myocardial biopsy 
specimens were fixed in a 10% formalin solution on 
phosphate buffer. Paraffin sections with a thickness of 
3–5 μm were prepared on a microtome, Microm HM 
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350. Hematoxylin-eosin, picrofuchsine, van Gieson 
staining and further staining of elastic fibers with 
resorcinol and Weigert fuchsine were used as survey 
histological stains. The histological examination was 
carried out using a software microscope complex that 
included AXIOSKOP 40 light microscope ZEISS, 
AxioCam MRc digital video camera, and Pentium 
4 computer. The obtained images, 20 for each 
histological specimen, were processed using a complex 
of hardware software visualization of morphological 
specimens, analysis, and registration of optical and 
morphometric indicators of “Video Test” with the 
program “Video-Test Morphology.” The diameter of 
the muscle fiber, the relative area of muscle tissue, 
its volume density, the number of nuclei, the average 
core area, the nuclear-cytoplasmic ratio, and the 
number of intramyocardial vessels were measured.[13] 
The statistical processing of data was carried out with 
the “Statistica 6.0” software package.[14] The values 
are represented as a mean ± standard mean (M ± m) 
median; the differences were considered significant at 
P < 0.05.
RESULTS AND DISCUSSION
Our study established that post-infarction remodeling 
was developing in elderly patients by several types: 
Early, late, and progressive [Table 1] remodeling. In 
this case, early remodeling was determined in 33%, 
late remodeling in 38%, and progressive remodeling 
in 29% of patients.
It was determined that the majority of elderly patients 
with coronary artery disease develop myocardial 
hypertrophy, and a small number of patients have a 
dilated LV cavity [Table 2].
Remodeling of myocardium after 6 months of 
supervision over elderly patients on the background of 
medication with the formation of concentric myocardial 
hypertrophy was established in 75% of subjects, and 
eccentric hypertrophy was established in 25%. The 
presence of concentric left ventricular (LV)remodeling 
without changing the geometry of the heart was found in 
28 (20%) patients, concentric hypertrophy in 77 patients 
(55%), and eccentric hypertrophy in 35 (25%). Milder 
course of CHF (FC I, II) was reliably detected in patients 
with concentric myocardial hypertrophy (P ˂ 0.01), 
while severe CHF (FC III, IV) was significantly 
more frequent in eccentric myocardial hypertrophy 
(P ˂ 0.01). In this case, the isolated diastolic function 
also differed. It was established that the isolated diastolic 
variant of CHF in elderly patients was determined 
overwhelmingly with concentric hypertrophy, then 
with concentric remodeling, and to a lesser extent with 
eccentric hypertrophy. At the same time, the change and 
damage of the systolic-diastolic function and the course 
of CHF reaches 76% in case of eccentric hypertrophy 
(P ˂ 0.01), to a lesser extent in concentric hypertrophy 
17%, and concentric remodeling 7%.
It is noteworthy that in comparison with the control 
group in elderly patients with CHF on the background 
of coronary artery disease with eccentric hypertrophy, 
a reliable decrease in E by 38% P < 0.05, A by 11.7% 
P < 0.05, E/A by 33.4% P < 0.01, and EF by 38.8% 
P < 0.001. At the same time, the group of concentric 
remodeling had a decrease in E by 27.8% P < 0.01, A 
by 23.9% P < 0.05, E/A by 8% P < 0.05, and EF by 
16.6% P < 0.05 [Table 3].
Thus, the morphometric study of myocardial tissue 
in patients with eccentric hypertrophy of the left 
Table 1: Post‑infarction remodeling in elderly patients during the 1st year after AMI (M±m)
Indicators n=140 Early remodeling n=46 Late remodeling n=53 Progressive remodeling n=41
Age, years 71.3±2 68.3±4 69.0±3
EDV, ml 112.3±9.0 141.2±6.9# 149.5±6.0#**
ESV, ml 69.2±13.4 80.0±4.9# 86.1±12.3
EF, % 44.2±17.9 40.8±6.3 38.4±4.1
P<0.05 compared with no remodeling; **P<0.01 compared with late remodeling; #P<0.001 compared with early remodeling. AMI: Acute myocardial 
infarction, EDV: End-diastolic volume, ESV: End-systolic volume
Table 2: Post‑infarction remodeling of the LV myocardium in elderly patients (M±m)
Indicators n=140 Nature of remodeling
Concentric 
remodeling n=28 (20)
Concentric 
hypertrophy n=77 (55)
Eccentric hypertrophy 
n=35 (25)
Age, years 68.9±5.9 66.4±6.8 64.1±5.1
CHF
FC I 7 (25) 13 (17.0) 3 (8.6)**
FC II 12 (42.8) 44 (57.0)* 9 (26.0) **
FC III 9 (32.2) 20 (26.0)* 15 (43.0)*
FC IV ‑ ‑ 8 (22.4)**
CHF variants systolic diastolic mixed 6 (15) 4 (5.2) 4 (11.4)
31 (77.5) 61 (79.2) 16 (45.7)**
3 (7.5) 12 (15.6)* 15 (42.9)**
*P<0.05; **Р<0.01 compared with previous groups. LV: Left ventricular, FC: Functional class, CHF: Chronic heart failure
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the nuclear-plasma index in the control group was 
significantly lower (0.246 ± 0.051) than in the group 
with eccentric hypertrophy (0.487 ± 0.136) and the 
group with pronounced concentric hypertrophy (0.731 ± 
0.176). There were no statistical differences in the area of 
connective tissue and the phenomena of perivascular and 
interstitial edema in all three groups.
The progressive increase in LV mass, the decrease in 
the coronary reserve as a result of blood flow mismatch 
with the needs of the LV myocardial mass, chronic 
overload and myocardial hypoxia, due to fibrosis[15] 
changes the electrophysiological properties of the 
myocardium, affects the cardiomyocyte contraction-
relaxation mechanism[16] and is a substrate of fatal 
Table 3: Diastolic and systolic CHF in elderly patients (M±m)
Indicators Control group 
n=15 (100)
Concentric 
remodeling 
n=20 (20)
Concentric 
hypertrophy 
n=77 (55)
Eccentric 
hypertrophy 
n=35 (25)
Δ; р
1 2 3 4 2–3 3–4
Е, sm·s−1 77.38±3.77 55.84±2.94** 53.89±2.76** 47.86±6.16** 1.95; >0.05 6.03; ˂0.05
А, sm·s−1 65.80±3.3 50.08±4.14** 55.62±3.42* 58.12±4.15* −5.54; ˂0.05 −2.5; >0.05
Е/А, un 1.2±0.34 1.1±0.18 0.9±0.24* 0.8±0.08** 0.2; ˂0.01 ˂0.001
EF, % 67.18±4.34 56.04±4.73** 62.92±4.35* 41.13±4.2** −6.88; ˂0.05 21.79; ˂0.01
*P<0.05; **P<0.01 compared with the control group. CHF: Chronic heart failure, EF: Ejection fraction
Figure 1: Study of myocardial tissue in a patient with 
eccentric hypertrophy of the left ventricle
Figure 2: Study of myocardial tissue in a patient with 
pronounced concentric hypertrophy of the left ventricle
Figure 3: Study of myocardial tissue in a patient without 
signs of remodeling
Figure 4: Study of myocardial tissue in a patient of the 
control group
ventricle revealed a significant reduction in the size of 
the cardiomyocyte nuclei (94.08 ± 16.41, P = 0.0057) 
(Figure. 1), in comparison with patients with concentric 
hypertrophy (Figure 2), with a group without signs of 
remodeling (Figure. 3), and control group (Figure 4). 
The assessment of myocardial autopsy in patients with 
severe concentric hypertrophy found a statistically 
significant increase in the size of cardiomyocyte nuclei 
(121.31 ± 30.96, P ≤ 0.05) as well as a decrease in 
the cytoplasm volume (165.85 ± 54.95, P = 0.051) 
in patients with eccentric hypertrophy of the LV and 
patients without signs of myocardial remodeling. It was 
established that patients with no signs of pathological 
remodeling of the LV myocardium have a smaller area 
of nuclei, a lack of pronounced polymorphism of forms, 
and a decrease in their number. It was determined that 
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rhythm disorders in this category of patients. This leads 
to an increase in the amount of collagen matrix in the 
myocardium and enhance in apoptosis processes. This 
leads to a subsequent stage of remodeling of the left 
ventricle, which leads to a set of changes in its shape and 
functioning in response to hemodynamic conditions 
and pathological processes in the myocardium. It has 
been established that the dilatation of LV cavities is 
the morphological substrate of these changes, which is 
the reason and evidence of the appearance of clinically 
significant CHF, which in our patients were manifested 
in higher FC of CHF arising and progressing with 
eccentric hypertrophy.
All forms of LV myocardial remodeling are accompanied 
by a decrease in both LV diastolic relaxation and 
atrial filling. In our study, the maximum reduction in 
diastolic relaxation was found in patients with eccentric 
hypertrophy, which is accompanied by the most 
significant drop in the ejection fraction. In concentric 
hypertrophy of the left ventricle of the heart and 
concentric remodeling, a decrease in diastolic filling and 
atrial filling is accompanied by the preservation of EF.
To date, to prevent the progression of CHF in the 
1st year of treatment of elderly patients after heart 
attack, a systematic evaluation of not only known 
systolic function indices but also the effect of 
medication on diastolic function is required, which 
is performed extremely rare and, as a rule, only in 
patients with so-called diastolic heart failure.
CONCLUSION
It was established that structural changes occur in 
the formation of post-infarction cardiosclerosis. 
Morphological studies revealed an increase in size and 
a decrease in the number of myocytes and an increase 
in the connective tissue matrix. The density of the 
myocardium increases accompanied by a diastolic 
LV disturbance. The existing chronic LV overload 
causes a structural and morphological restructuring 
of myocardial tissue, which is characterized by the 
presence of hypertrophy, dilatation, and subsequently 
the change in the geometry of the heart. Remodeling of 
the myocardium is the integral substrate that determines 
the occurrence and progression of CHF in elderly 
patients. An important factor in the development of these 
processes is the age factor. Patients over 60 years with 
post-infarction cardiosclerosis have a reliable increase 
in their volumes of the left ventricle; their rate of circular 
shortening of the myocardial fibers decreases and the 
fraction of the LV ejection decreases. At the same time, 
with aging, there is an increase in the ischemic load on 
the myocardium and a decrease in the reserve capacities 
of the cardiovascular system. Cardiovascular diseases 
are extremely common in elderly patients and are the 
main cause of their death. The increase in the number Source of support: Nil; Conflict of interest: None Declared
of elderly people worldwide is accompanied by an 
increase in the number of patients with cardiovascular 
diseases. The available guidelines for the management 
of patients with cardiovascular diseases are mainly 
based on studies which either included small number 
or none of elderly patients. In this regard, the evidence 
base of recommendations for the treatment of common 
pathological conditions in the elderly is insufficient. To 
make the best decision when managing elderly patients 
with CHF, the clinician should know not only the 
evidence base of the research but also take into account 
the changes in the cardiovascular system that occurs in 
the process of aging.
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